智翔金泰：关于GR1803注射液系统性红斑狼疮适应症获得药物临床试验批准通知书的公告

Core Viewpoint - Zhixiang Jintai has received approval from the National Medical Products Administration for the clinical trial application of its product GR1803 injection for systemic lupus erythematosus [2] Group 1 - The company announced the receipt of the clinical trial approval notice on the evening of September 10 [2] - The approved clinical trial is for the indication of systemic lupus erythematosus [2]